Twice weekly. Steady by design.
Prescription estradiol patches provide steady transdermal delivery with a twice-weekly change schedule.
About 10 minutes. No charge unless your clinician approves.
The format that knows how to disappear.
Estradiol is the estrogen that declines through perimenopause and menopause, a shift associated with hot flashes, night sweats, disrupted sleep, and vaginal dryness. The patch delivers bioidentical estradiol continuously through the skin from a small adhesive worn on the lower abdomen or buttock.
The molecule is familiar. The real product decision here is the format.
You change the patch on the same two days each week. Between those moments there is nothing to measure, rub in, or remember. The patch is designed to release a controlled dose continuously, making steadiness part of both the delivery and the routine.
For the right patient, that low-maintenance design is not a trivial convenience. Hormone therapy works inside an already full life, and a format that asks for less daily attention can be easier to live with consistently.
The patch offers steady delivery with low daily friction. Two changes a week, continuous transdermal delivery between them, and practical guidance for placement, showering, and the occasional loose patch.
Read the evidence →For women who want hormone therapy off the daily to-do list.
The Full Calendar
Work, family, training, travel, and everything in between already compete for your attention. Two predictable patch changes a week may fit a real life better than another daily ritual.
The Steady-Routine Person
You like a treatment that stays put and delivers continuously between changes. The fewer times you have to think about the dose, the easier it is to make the therapy part of normal life.
Done With Waiting It Out
Hot flashes and broken sleep have been treated like something you are supposed to endure because menopause is natural. Natural does not mean clinically irrelevant. It deserves a real conversation about whether treatment fits you.
Whether the patch suits your symptoms and your history is determined by a licensed provider from your Assessment. Compounded by a licensed 503A pharmacy and not an FDA-approved drug product.
This might not be the right fit if:
- History of breast cancer or another estrogen-dependent malignancy
- Unexplained vaginal bleeding
- History of blood clots, stroke, or heart attack
- Active liver disease
- Pregnancy or planned pregnancy
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Estradiol Patches, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Bioidentical estradiol released continuously through the skin
- Patch changed on the same two days each week
- Worn on the lower abdomen or buttock as directed
- Paired with micronized progesterone when you have a uterus, per standard of care
- Dose reviewed and adjusted through your ongoing provider relationship
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Hormones & Vitality.
Estradiol Gel
Menopause symptoms should not set the pace.
Prescription estradiol gel delivers systemic estrogen through the skin in an adjustable daily format.
Estradiol Tablet
A familiar form, backed by serious hormone care.
Prescription oral estradiol puts established hormone therapy into a familiar, straightforward daily form.
Estradiol Vaginal Cream
Local treatment for an intimate problem.
Prescription vaginal estradiol delivers local treatment directly to the tissue at the center of the concern.
What the research shows
Higher doses separated from placebo at week 4; the lowest needed a third trial.
The detail
The twice-weekly estradiol transdermal system was studied in two controlled clinical trials in a total of 356 women, in which the 0.075 mg and 0.1 mg per day doses were superior to placebo in relieving vasomotor symptoms at week 4 and maintained that through weeks 8 and 12. Because the 0.0375 mg and 0.05 mg doses did not separate from placebo until roughly week 6 in those trials, a third 12-week placebo-controlled trial was run in 255 women whose baseline mean was 11.5 hot flushes a day; the lowest 0.0375 mg dose was superior to placebo on both frequency and severity at weeks 4, 8 and 12.1
Weekly hot flushes fell 67 and 72 percent on patch, against 18.1 percent on placebo.
The detail
In a separate randomized trial of 214 women aged 25 to 74 assigned to a 0.05 mg per day estradiol patch, a 0.1 mg per day patch or placebo, with adequate efficacy data from 191, the mean weekly hot flush rate across all treatment cycles fell from 46 to 20 on the 0.05 mg patch, a 67 percent reduction, and from 52 to 16 on the 0.1 mg patch, a 72 percent reduction, against a fall from 53 to 46 on placebo, an 18.1 percent reduction. Both estradiol groups were statistically significantly better than placebo, p less than 0.05.2
Lumbar spine bone density rose on every estradiol dose and fell on placebo.
The detail
Bone was measured in its own trial. In a 2-year double-blind, randomized, placebo-controlled, parallel-group study, 261 surgically or naturally menopausal women within five years of menopause and without osteoporosis, mean age 52, were assigned to one of four doses of the twice-weekly estradiol transdermal system, 194 women, or placebo, 67 women, with non-hysterectomized women also taking oral medroxyprogesterone acetate 2.5 mg a day. Lumbar spine bone mineral density rose in every estradiol dose group and fell in the placebo group, and every estradiol dose was significantly superior to placebo, p less than 0.05, at all time points except the 0.05 mg dose at 6 months.1
The two WHI trials did not find the same thing, and timing changed the coronary result.
The detail
The Women’s Health Initiative ran two separate randomized, double-blind, placebo-controlled trials, and they did not find the same thing. In 16,608 postmenopausal women aged 50 to 79 with a uterus given oral conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg, hazard ratios over a mean 5.2 years were 1.29 for coronary heart disease, 95 percent confidence interval 1.02 to 1.63, 1.26 for invasive breast cancer, 1.00 to 1.59, 1.41 for stroke, 1.07 to 1.85, and 2.13 for pulmonary embolism, 1.39 to 3.25.3 In 10,739 women with a prior hysterectomy given conjugated equine estrogens alone for an average 6.8 years, stroke rose, hazard ratio 1.39, 1.10 to 1.77, hip fracture fell, 0.61, 0.41 to 0.91, coronary heart disease was unchanged, 0.91, 0.75 to 1.12, and breast cancer was 0.77, 0.59 to 1.01.4 A prespecified analysis of both trials found the coronary result varied with time since menopause, hazard ratio 0.76 at under 10 years, 1.10 at 10 to 19 years and 1.28 at 20 or more years, p for trend 0.02, while stroke risk was elevated regardless of timing, 1.32, 1.12 to 1.56.5
Oral therapy carried higher venous thromboembolism odds; transdermal was not associated with increased risk.
The detail
Route has been studied observationally rather than randomly. In two nested case-control studies covering 80,396 women aged 40 to 79 with a first venous thromboembolism between 1998 and 2017 and 391,494 matched controls drawn from UK general practice records, oral hormone therapy was associated with an adjusted odds ratio of 1.58 for venous thromboembolism, 95 percent confidence interval 1.52 to 1.64, while transdermal preparations were not associated with increased risk, adjusted odds ratio 0.93, 0.87 to 1.01.6
What it does not show
No approved or established use for anti-aging, longevity, cognitive protection or cardiovascular prevention.
The detail
The approved uses are narrow. Estradiol transdermal system labeling covers moderate to severe vasomotor symptoms due to menopause, moderate to severe symptoms of vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevention of postmenopausal osteoporosis. There is no approved or established use for anti-aging, longevity, cognitive protection or cardiovascular prevention, and the labeling states that estrogen therapy should not be used for the prevention of cardiovascular disease or dementia.12
Placebo arms fell 57.7 percent, and the symptom trials ran 11 to 12 weeks.
The detail
Placebo mattered and the trials were short. In the 214-woman patch trial the placebo group still recorded an 18.1 percent fall in weekly hot flushes over 11 weeks, and a Cochrane review of 24 double-blind randomized trials in 3,329 women recorded a 57.7 percent reduction in the placebo arms. The symptom trials here ran 11 to 12 weeks; the bone trial ran two years and measured bone density, not fractures.127
The patch label still carries the older four-part boxed warning.
The detail
The boxed warning is in transition and the patch has not moved yet. On November 10, 2025 the FDA asked manufacturers of menopausal hormone therapy to remove the cardiovascular disease, breast cancer and probable dementia language from the boxed warning while retaining the endometrial cancer boxed warning for systemic estrogen-alone products, and the first revised labels were approved on February 12, 2026. As of August 2026 no estradiol transdermal system label posted on DailyMed has been revised to that shorter form; the approved patch labeling still carries the older four-part boxed warning. Neither the older wording nor the revision should be read as a change in the underlying findings: the Women’s Health Initiative results were relocated within the label, not withdrawn.189
No trial cited here tested a compounded transdermal preparation, and the route data cannot prove cause.
The detail
The observational route data cannot establish cause, and the trials tested approved products. A nested case-control study can show that transdermal users had no measured excess of venous thromboembolism; it cannot prove the route is what made the difference, because women are not randomized to it. Separately, the Women’s Health Initiative tested oral conjugated equine estrogens rather than transdermal estradiol, the labeling states the relevance of those findings to other routes is not known, and no trial cited here tested a compounded transdermal preparation.1346
- FDA-approved prescribing information, VIVELLE-DOT (estradiol transdermal system), Sandoz Inc, label version 17 published November 2023.DailyMed
- FDA-approved prescribing information, CLIMARA (estradiol transdermal system), Bayer HealthCare Pharmaceuticals Inc, label version 25 published March 2026.DailyMed
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal… JAMA. 2002.
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with… JAMA. 2004.
- Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by… JAMA. 2007.
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism… BMJ. 2019.
- MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus… Cochrane Database Syst Rev. 2004;(4):CD002978.
- US Food and Drug Administration. FDA requests labeling changes related to safety information to clarify… Drug safety statement, November 10, 2025.FDA
- US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. Press announcement, February 12, 2026.FDA
Approved estradiol labeling carries a boxed warning that estrogen without a progestogen increases the risk of endometrial cancer in a woman who still has a uterus, so unopposed systemic estrogen is not an appropriate plan in that situation and progesterone belongs in the conversation.
Do not use if you have
- A history of breast cancer or another estrogen-dependent cancer
- Unexplained vaginal bleeding
- A prior blood clot, stroke or heart attack
- An inherited clotting disorder
- Liver disease
- A known anaphylactic reaction, angioedema, or hypersensitivity to the patch itself
- Pregnancy
Serious risks
- Stroke, deep vein thrombosis and pulmonary embolism
- Gallbladder disease
- Probable dementia in women who begin therapy at 65 or older
- Breast cancer when estrogen and a progestogen are taken together over longer use
Commonly reported
- Redness or irritation of the skin under the patch
- Headache
- Breast tenderness
- Back pain
- Irregular vaginal bleeding or spotting
Because it is a patch
- Delivery through the skin avoids the first pass through the liver that a swallowed dose takes
- It does not remove the risks that belong to the estrogen class
The effects reported most often are listed here, along with the risks that belong to the estrogen class. Your provider weighs your age, your history, and how long you have been postmenopausal before prescribing, and keeps that judgment open as your care continues.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Heat, humidity, movement, and skin can all affect adhesion. If a patch loosens, press it back down firmly; if it comes off, replace it with a fresh one and return to your regular change days. Your care team can help with placement choices that work better for your skin and routine.
You complete your Assessment online and a licensed provider reviews it. Your clinician may message you with questions before making a decision because hormone therapy deserves more than a rubber-stamp intake. If approved, the prescription moves to the pharmacy for fulfillment.
Systemic estrogen carries risks your provider discusses with you directly, including blood clots and stroke, and combined hormone therapy has been associated with increased breast cancer risk over longer use. Your personal risk depends on age, history, dose, route, and timing since menopause. That conversation happens before anything ships, and it continues through your care.